Literature DB >> 11789189

[Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula "tiangui fang"].

J Hou1, J Yu, M Wei.   

Abstract

OBJECTIVE: To observe the efficacy of Chinese herbal formula "Tiangui Fang" (TGF) in hyperandrogenism and hyperinsulinism patients of polycystic ovarian syndrome (PCOS), and compare with western medicine metformin.
METHODS: Twenty-two anti-clomiphen citrite patients were divided into two treatment groups: "Tiangui Fang" (n = 10) and metformin (n = 12) for three months. Insulin response during oral glucose tolerance test and serum level of LH, FSH, testosterone (T), estradiol (E2) and waist to hip ratio (WHR), body mass index (BMI) were measured before and after treatment.
RESULTS: After treatment for three months with metformin or TGF, fasting and the integrated insulin response to the glucose load decreased. Treated by metformin 4 out of 8 patients had restoration of menstrual cyclicity and 2 of them had double phase bases body temperature (BBT). This was accompanied by lowering in serum logT/E2 but had no significant difference, the BMI, WHR and serum E2, LH:FSH ratio were not changed. Treated by TGF for three months, 6 out of 8 patients had restoration of menstrual cyclicity and double phase BBT. This was accompanied by significant lowering in serum T, logT/E2 and BMI (P < 0.05), serum LH:FSH ratio were not changed.
CONCLUSION: Both metformin and TGF can reduce the high concentration of insulin in PCOS patients and induce ovulation, the herbal formula has a better efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11789189

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  9 in total

1.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

Review 2.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 3.  Chinese herbal medicine for subfertile women with polycystic ovarian syndrome.

Authors:  Kunyan Zhou; Jing Zhang; Liangzhi Xu; Taixiang Wu; Chi Eung Danforn Lim
Journal:  Cochrane Database Syst Rev       Date:  2016-10-12

Review 4.  Treating gynaecological disorders with traditional Chinese medicine: a review.

Authors:  Jue Zhou; Fan Qu
Journal:  Afr J Tradit Complement Altern Med       Date:  2009-07-03

Review 5.  The Treatment with Complementary and Alternative Traditional Chinese Medicine for Menstrual Disorders with Polycystic Ovary Syndrome.

Authors:  Yuehui Zhang; Xiaozhu Guo; Shuting Ma; Haoyue Ma; Hang Li; Yi Wang; Zhen Qin; Xiaoke Wu; Yaguang Han; Yanhua Han
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-17       Impact factor: 2.629

6.  Chinese herbal medicine for subfertile women with polycystic ovarian syndrome.

Authors:  Kunyan Zhou; Jing Zhang; Liangzhi Xu; Chi Eung Danforn Lim
Journal:  Cochrane Database Syst Rev       Date:  2021-06-04

7.  Use of Bao Gui capsule in treatment of a polycystic ovary syndrome rat model.

Authors:  Yuling Lian; Fangui Zhao; Wenjun Wang
Journal:  Mol Med Rep       Date:  2020-01-20       Impact factor: 2.952

Review 8.  Progress of integrative Chinese and Western medicine in treating polycystic ovarian syndrome caused infertility.

Authors:  Juan-juan Song; Miao-e Yan; Xiao-ke Wu; Li-hui Hou
Journal:  Chin J Integr Med       Date:  2006-12       Impact factor: 2.626

9.  Effects of tanshinone on hyperandrogenism and the quality of life in women with polycystic ovary syndrome: protocol of a double-blind, placebo-controlled, randomised trial.

Authors:  Wenjuan Shen; Yuehui Zhang; Wei Li; Jing Cong; Ying Zhou; Ernest H Y Ng; Xiaoke Wu
Journal:  BMJ Open       Date:  2013-10-25       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.